What is the current stock price of Lobe Sciences Ltd. (LOBEF)?

As of the latest market data, Lobe Sciences Ltd. (LOBEF) is trading at $0.01. The stock has seen a loss of -3.33% today.

Does Lobe Sciences Ltd. (LOBEF) pay a dividend?

Based on current data, Lobe Sciences Ltd. does not have a confirmed active dividend policy.

What is the market cap of Lobe Sciences Ltd.?

The current market capitalization of Lobe Sciences Ltd. (LOBEF) is approximately unavailable.

LOBEF

Lobe Sciences Ltd.·Healthcare

0.01

3.333%(−0.00)

Close Price

Last Updated: — ET

52W L: $0.0052W H: $0.10

LOBEF NEWS

accessnewswire.com

May 6

Lobe Sciences Ltd. Announces Participation in the D.

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced that its Chief Executive Officer, Dr. Frederick D.

accessnewswire.com

May 6

Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced its unaudited interim financial results for the second quarter of fiscal 2026 ended February 28, 2026 ("Q2 2026") and provided an operational update.

accessnewswire.com

Apr 23

Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders

VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, welcomes the recent White House Executive Order supporting the advancement of novel treatments for neurological and mental health disorders.

accessnewswire.com

Apr 21

Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services

VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs, is pleased to announce that it has engaged Massive Intelligence Pty Ltd ("Massive Intelligence") to provide investor relations and corporate communications services.

accessnewswire.com

Apr 20

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 20, 2026 / Lobe Sciences Ltd.

accessnewswire.com

Apr 10

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 10, 2026 / Lobe Sciences Ltd.

Company Profile

Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2023-08-24

Beta

-0.08

Websitewww.lobesciences.com↗